Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immatics
Biotech
ESMO: Bristol Myers axes Immatics' bispecific after $150M bet
Immatics is the latest partner to get a termination notice, leaving it in full control of a bispecific that BMS picked up for $150 million in 2021.
Nick Paul Taylor
Sep 16, 2024 6:59am
With $1.7B Immatics deal, Moderna bets again on cancer vaccines
Sep 11, 2023 8:12am
Immatics' stock soars on PRAME prospect's solid tumor data
May 3, 2023 9:35am
GSK severs Immatics partnership in further T-cell retreat
Nov 17, 2022 11:00am
BMS-backed Immatics touts early data, prompting $110M offering
Oct 10, 2022 1:23pm
Immatics finds a pan-cancer target for T-cell therapies
Aug 31, 2022 4:20pm
